Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery

Andra Mihali Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Molecular Therapeutics, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Molecular Therapeutics, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA

Shreya Subramani Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Molecular Therapeutics, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Molecular Therapeutics, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA

Genevieve Kaunitz Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Molecular Therapeutics, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Molecular Therapeutics, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA

Stephen Rayport Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Molecular Therapeutics, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA; Department of Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 62, New York, NY 10032, USA. [email protected]

Inna Gaisler-Salomon Department of Psychology, University of Haifa, Psychobiology Labs, Rabin Building 5059, Haifa 31905, Israel. [email protected]; Department of Psychology, University of Haifa, Psychobiology Labs, Rabin Building 5059, Haifa 31905, Israel. [email protected]

Abstract

Complex psychiatric disorders, such as schizophrenia, arise from a combination of genetic, developmental, environmental and social factors. These vulnerabilities can be mitigated by adaptive factors in each of these domains engendering resilience. Modeling resilience in mice using transgenic approaches offers a direct path to intervention, as resilience mutations point directly to therapeutic targets. As prototypes for this approach, we discuss the three mouse models of schizophrenia resilience, all based on modulating glutamatergic synaptic transmission. This motivates the broader development of schizophrenia resilience mouse models independent of specific pathophysiological hypotheses as a strategy for drug discovery. Three guiding validation criteria are presented. A resilience-oriented approach should identify pharmacologically tractable targets and in turn offer new insights into pathophysiological mechanisms.

Keywords::

Financial & competing interests disclosure

The authors’ research on the GLS1 model has been supported by NIH grants K02-DA00356, R21-DA14055, P50-MH066171 and R01-MH087758, and NARSAD (S Rayport), and Israel Science Foundation Young Investigator grant 484/10 and Binational Science Foundation 2009301 (I Gaisler-Salomon). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery

Information for

Open access

Opportunities

Help and information

Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery

Abstract

Financial & competing interests disclosure

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature